000127825 001__ 127825
000127825 005__ 20241125101158.0
000127825 0247_ $$2doi$$a10.3390/ph16081161
000127825 0248_ $$2sideral$$a134958
000127825 037__ $$aART-2023-134958
000127825 041__ $$aeng
000127825 100__ $$aPueyo-Val, Javier$$uUniversidad de Zaragoza
000127825 245__ $$aReports of Symptoms Associated with Supraventricular Arrhythmias as a Serious Adverse Drug Reaction in the Spanish Pharmacovigilance Database
000127825 260__ $$c2023
000127825 5060_ $$aAccess copy available to the general public$$fUnrestricted
000127825 5203_ $$aThis study aimed to determine the type of drugs reported as suspected of causing severe supraventricular arrhythmias from the Spanish Human Pharmacovigilance System database. A total of 1053 reports were analysed, of which 526 (50%) were on men and 516 (49%) were on women. The most affected age group was the over-65s, with 593 reports (56%). Of the 1613 drugs, those belonging to the cardiovascular system (ATC Group C) were the most numerous (414 reports, 26%), with digoxin being the most frequent drug (49 reports, 12%). Other common groups were antiinfectives for systemic use (ATC Group J; 306 reports, 19%), antineoplastic and immunomodulating agents (ATC Group L; 198 reports, 12%), and nervous system drugs (ATC Group N; 185 reports, 11%). The most common supraventricular arrhythmia was atrial fibrillation (561 reports, 51%). Regarding outcomes, 730 (66%) patients recovered, 76 (7%) did not recover, 25 (3%) recovered but with sequelae, and 23 (2%) resulted in death. This study revealed that certain drugs have reported to be associated more frequently to supraventricular arrhythmias as serious adverse reactions, especially in the older population. Proper clinical management and effective strategies to ensure medication appropriateness should always be considered to improve patient safety when prescribing drugs.
000127825 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000127825 590__ $$a4.3$$b2023
000127825 592__ $$a0.845$$b2023
000127825 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 354 = 0.195$$c2023$$dQ1$$eT1
000127825 593__ $$aPharmaceutical Science$$c2023$$dQ1
000127825 591__ $$aCHEMISTRY, MEDICINAL$$b20 / 72 = 0.278$$c2023$$dQ2$$eT1
000127825 593__ $$aDrug Discovery$$c2023$$dQ2
000127825 593__ $$aMolecular Medicine$$c2023$$dQ2
000127825 594__ $$a6.1$$b2023
000127825 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000127825 700__ $$aAvedillo-Salas, Ana$$uUniversidad de Zaragoza
000127825 700__ $$aBerdún-Viñegra, Pablo
000127825 700__ $$aPueyo-Val, Olga María
000127825 700__ $$0(orcid)0000-0001-8064-8138$$aFanlo-Villacampa, Ana$$uUniversidad de Zaragoza
000127825 700__ $$0(orcid)0000-0002-7239-1966$$aNavarro-Pemán, Cristina$$uUniversidad de Zaragoza
000127825 700__ $$0(orcid)0000-0002-6485-1926$$aLanuza-Giménez, Francisco Javier$$uUniversidad de Zaragoza
000127825 700__ $$aIoakeim-Skoufa, Ignatios
000127825 700__ $$0(orcid)0000-0003-4629-6743$$aVicente-Romero, Jorge$$uUniversidad de Zaragoza
000127825 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000127825 773__ $$g16, 8 (2023), 1161 [12 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000127825 8564_ $$s824592$$uhttps://zaguan.unizar.es/record/127825/files/texto_completo.pdf$$yVersión publicada
000127825 8564_ $$s2678744$$uhttps://zaguan.unizar.es/record/127825/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000127825 909CO $$ooai:zaguan.unizar.es:127825$$particulos$$pdriver
000127825 951__ $$a2024-11-22-12:10:18
000127825 980__ $$aARTICLE